| Tyrosine kinase activity and transformation potency of bcr-abl oncogene products TG Lugo, AM Pendergast, AJ Muller, ON Witte Science 247 (4946), 1079-1082, 1990 | 1783 | 1990 |
| Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy AJ Muller, JB DuHadaway, PS Donover, E Sutanto-Ward, GC Prendergast Nature medicine 11 (3), 312-319, 2005 | 1275 | 2005 |
| Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses DY Hou, AJ Muller, MD Sharma, J DuHadaway, T Banerjee, M Johnson, ... Cancer research 67 (2), 792-801, 2007 | 731 | 2007 |
| Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan R Metz, JB DuHadaway, U Kamasani, L Laury-Kleintop, AJ Muller, ... Cancer research 67 (15), 7082-7087, 2007 | 624 | 2007 |
| Discovery of IDO1 inhibitors: from bench to bedside GC Prendergast, WP Malachowski, JB DuHadaway, AJ Muller Cancer research 77 (24), 6795-6811, 2017 | 552 | 2017 |
| Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer GC Prendergast, C Smith, S Thomas, L Mandik-Nayak, L Laury-Kleintop, ... Cancer immunology, immunotherapy 63, 721-735, 2014 | 541 | 2014 |
| BCR First Exon Sequences Specifically Activate the BCR/ABL Tyrosine Kinase Oncogene of Philadelphia ChromosomePositive Human Leukemias AJ Muller, JC Young, AM Pendergast, M Pondel, NR Landau, DR Littman, ... Molecular and cellular biology 11 (4), 1785-1792, 1991 | 525 | 1991 |
| Indoleamine 2, 3‐dioxygenase in T‐cell tolerance and tumoral immune escape JB Katz, AJ Muller, GC Prendergast Immunological reviews 222 (1), 206-221, 2008 | 523 | 2008 |
| BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner AM Pendergast, AJ Muller, MH Havlik, Y Maru, ON Witte Cell 66 (1), 161-171, 1991 | 509 | 1991 |
| The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists S Thomas, J Izard, E Walsh, K Batich, P Chongsathidkiet, G Clarke, ... Cancer research 77 (8), 1783-1812, 2017 | 427 | 2017 |
| IDO is a nodal pathogenic driver of lung cancer and metastasis development C Smith, MY Chang, KH Parker, DW Beury, JB DuHadaway, HE Flick, ... Cancer discovery 2 (8), 722-735, 2012 | 350* | 2012 |
| Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors AJ Muller, PA Scherle Nature Reviews Cancer 6 (8), 613-625, 2006 | 339 | 2006 |
| Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase AJ Muller, MD Sharma, PR Chandler, JB DuHadaway, ME Everhart, ... Proceedings of the National Academy of Sciences 105 (44), 17073-17078, 2008 | 291 | 2008 |
| Indoleamine 2, 3-dioxygenase and its therapeutic inhibition in cancer GC Prendergast, WJ Malachowski, A Mondal, P Scherle, AJ Muller International review of cell and molecular biology 336, 175-203, 2018 | 274 | 2018 |
| Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond AJ Muller, MG Manfredi, Y Zakharia, GC Prendergast Seminars in immunopathology 41, 41-48, 2019 | 251 | 2019 |
| Structure− activity study of brassinin derivatives as indoleamine 2, 3-dioxygenase inhibitors P Gaspari, T Banerjee, WP Malachowski, AJ Muller, GC Prendergast, ... Journal of medicinal chemistry 49 (2), 684-692, 2006 | 237 | 2006 |
| Indoleamine 2, 3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors S Kumar, WP Malachowski, JB DuHadaway, JM LaLonde, PJ Carroll, ... Journal of medicinal chemistry 51 (6), 1706-1718, 2008 | 213 | 2008 |
| IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation R Metz, C Smith, JB DuHadaway, P Chandler, B Baban, LMF Merlo, ... International immunology 26 (7), 357-367, 2014 | 212 | 2014 |
| A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2, 3-dioxygenase T Banerjee, JB Duhadaway, P Gaspari, E Sutanto-Ward, DH Munn, ... Oncogene 27 (20), 2851-2857, 2008 | 209 | 2008 |
| Structure based development of phenylimidazole-derived inhibitors of indoleamine 2, 3-dioxygenase S Kumar, D Jaller, B Patel, JM LaLonde, JB DuHadaway, ... Journal of medicinal chemistry 51 (16), 4968-4977, 2008 | 201 | 2008 |
